Yazar "Kilickap, S." seçeneğine göre listele
Listeleniyor 1 - 9 / 9
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Cemiplimab for advanced non-small cell lung cancer: Squamous subgroup analysis for EMPOWER-Lung 1 and 3(Elsevier, 2023) Makharadze, T.; Gogishvili, M.; Melkadze, T.; Baramidze, A.; Sezer, A.; Kilickap, S.; Gumus, M.[Abstract Not Available]Öğe Cemiplimab-Based Treatment in Advanced NSCLC With Liver Metastases: Updated Analysis From EMPOWER-Lung 1 and EMPOWER-Lung 3(Elsevier Science Inc, 2023) Baramidze, A.; Gessner, C.; Gogishvili, M.; Sezer, A.; Makharadze, T.; Kilickap, S.; Gumus, M.[Abstract Not Available]Öğe Disease Progression on PROs in Patients With aNSCLC With PD-L1 ?50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1(Elsevier Science Inc, 2023) Gumus, M.; Kilickap, S.; Sezer, A.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; He, X.[Abstract Not Available]Öğe EMPOWER-Lung 1: Cemiplimab (CEMI) monotherapy as first-line (1L) treatment of patients ( pts) with brain metastases from advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ?50%-3-year update(Elsevier Science Inc, 2023) Kilickap, S.; Ozguroglu, M.; Sezer, A.; Gumus, M.; Bondarenko, I.; Gogishvili, M.; Turk, H. M.[Abstract Not Available]Öğe Metastasis-directed radiotherapy for non-small cell lung cancer failured under TKI: A case report and literature review(Elsevier, 2023) Kahvecioglu, A.; Kilickap, S.; Hurmuz, P.Although tyrosine kinase inhibitors (TKI) have revolutionized the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer (ALKr-NSCLC), radiotherapy (RT) still plays an essential role for treatment of both intracranial and extracranial metastases, particularly for patients experienced a TKI-failure. We reported the case of a 38-year-old woman with metastatic ALKr-NSCLC who received whole-brain radiotherapy (RT) for multiple brain metastases (BMs), initially. After RT, alectinib was initiated and the patient had a good clinico-radiological response in both intracranial and extracranial regions. However, intracranial progression was developed and, stereotactic radiosurgery (SRS) was applied to the four progressed BMs. Two months after SRS, all BMs disappeared. While patient was using alectinib, a recurrent lung lesion, a hilar lymph node and bone metastasis were detected. Stereotactic body radiother-apy (SBRT) was applied to all metastatic sites and, alectinib was continued again. Three months after SBRT, a complete response was obtained. She has been alive with the initial systemic therapy agent for more than 4 years without evidence of neither disease nor toxicity. SRS/SBRT may eradicate the TKI-resistant tumoral clones and it may prevent switching the systemic therapy, even if there is a failure. (c) 2023 Published by Elsevier Masson SAS on behalf of Societe franc,aise de radiotherapie oncologique (SFRO).Öğe Opinions of medical oncologists on vaccination in cancer patients(Springer, 2022) Ozdemir, N.; Aktas, B. Y.; Kilickap, S.; Bayraktar-Ekincioglu, A.[Abstract Not Available]Öğe Patient-reported outcomes (PROs) in patients with advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ?50% receiving cemiplimab (CEMI) monotherapy vs chemotherapy (CHEMO): EMPOWER-Lung 1 liver metastases subpopulation(Elsevier Science Inc, 2023) Baramidze, A.; Gessner, C.; Gogishvili, M.; Sezer, A.; Makharadze, T.; Kilickap, S.; Gumus, M.[Abstract Not Available]Öğe Three-year Outcomes per PD-L1 Status and Continued Cemiplimab Beyond Progression plus Chemotherapy: EMPOWER-Lung 1(Elsevier Science Inc, 2023) Garassino, M. C.; Kilickap, S.; Ozguroglu, M.; Sezer, A.; Gumus, M.; Bondarenko, I.; Gogishvili, M.[Abstract Not Available]Öğe TREATMENT INEQUITIES AMONG CANCER PATIENTS DUE TO REIMBURSEMENT: FROM THE PERSPECTIVE OF 130 MEDICAL ONCOLOGISTS(Elsevier Science Inc, 2022) Karacin, C.; O, Hoca; Kilickap, S.[Abstract Not Available]
